The iconic rise of Viagra has firmly established as a benchmark of pharmaceutical success, however its future within the broader sector now presents questions about future yields . Copycat versions are diminishing patent protection , causing anxieties that investing in companies closely tied to Viagra's previous influence could be a speculative mov